MGMT and neoplasm: Hypermethylation of the MGMT promoter is expected to result in decreased MGMT mRNA/protein expression, which reduces the capacity of tumor cells to repair the lethal O6-methylguanine lesions produced by alkylating agents and renders these tumors more susceptible to these agents, including temozolomide (TMZ; refs. 3–5).